These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28741307)

  • 1. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.
    Kondili LA; Romano F; Rolli FR; Ruggeri M; Rosato S; Brunetto MR; Zignego AL; Ciancio A; Di Leo A; Raimondo G; Ferrari C; Taliani G; Borgia G; Santantonio TA; Blanc P; Gaeta GB; Gasbarrini A; Chessa L; Erne EM; Villa E; Ieluzzi D; Russo FP; Andreone P; Vinci M; Coppola C; Chemello L; Madonia S; Verucchi G; Persico M; Zuin M; Puoti M; Alberti A; Nardone G; Massari M; Montalto G; Foti G; Rumi MG; Quaranta MG; Cicchetti A; Craxì A; Vella S;
    Hepatology; 2017 Dec; 66(6):1814-1825. PubMed ID: 28741307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
    Chahal HS; Marseille EA; Tice JA; Pearson SD; Ollendorf DA; Fox RK; Kahn JG
    JAMA Intern Med; 2016 Jan; 176(1):65-73. PubMed ID: 26595724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
    Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
    Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
    Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
    Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy.
    Ruggeri M; Romano F; Basile M; Coretti S; Rolli FR; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2018 Oct; 16(5):711-722. PubMed ID: 30039348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.
    Popping S; Hullegie SJ; Boerekamps A; Rijnders BJA; de Knegt RJ; Rockstroh JK; Verbon A; Boucher CAB; Nichols BE; van de Vijver DAMC
    PLoS One; 2019; 14(1):e0210179. PubMed ID: 30629662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    Maunoury F; Clément A; Nwankwo C; Levy-Bachelot L; Abergel A; Di Martino V; Thervet E; Durand-Zaleski I
    PLoS One; 2018; 13(3):e0194329. PubMed ID: 29543897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.
    Leidner AJ; Chesson HW; Xu F; Ward JW; Spradling PR; Holmberg SD
    Hepatology; 2015 Jun; 61(6):1860-9. PubMed ID: 25677072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data.
    Marcellusi A; Viti R; Kondili LA; Rosato S; Vella S; Mennini FS;
    Pharmacoeconomics; 2019 Feb; 37(2):255-266. PubMed ID: 30378086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China.
    Liu Y; Zhang H; Zhang L; Zou X; Ling L
    Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A; San Miguel R; Mar J
    Pharmacoeconomics; 2013 Oct; 31(10):919-31. PubMed ID: 24000086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
    Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
    Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
    Obach D; Deuffic-Burban S; Esmat G; Anwar WA; Dewedar S; Canva V; Cousien A; Doss W; Mostafa A; Pol S; Buti M; Siebert U; Fontanet A; Mohamed MK; Yazdanpanah Y
    Clin Infect Dis; 2014 Apr; 58(8):1064-71. PubMed ID: 24510934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    Deuffic-Burban S; Obach D; Canva V; Pol S; Roudot-Thoraval F; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    Suenaga R; Suka M; Hirao T; Hidaka I; Sakaida I; Ishida H
    PLoS One; 2021; 16(4):e0248748. PubMed ID: 33793594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients].
    Buti M; Gros B; Oyagüez I; Andrade RJ; Serra MA; Turnes J; Casado MA
    Farm Hosp; 2014 Sep; 38(5):418-29. PubMed ID: 25344136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
    Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
    Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
    Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
    J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.